Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Christopher J. Darus"'
Autor:
Nicole M. Kretzer, Fernanda B. Musa, Christopher J. Darus, Nancy Biery, Roshanthi Weerasinghe, Ann Vita, Shwetha Pindikuri, Grace Li, Amy S. Parrish, Charles W. Drescher
Publikováno v:
Gynecologic Oncology Reports. 44:S25-S26
Publikováno v:
International Journal of Gynecologic Cancer. 31:209-214
BackgroundAs ovarian cancer treatment shifts to provide more complex aspects of care at high-volume centers, almost a quarter of patients, many of whom reside in rural counties, will not have access to those centers or receive guideline-based care.Ob
Autor:
Christopher J. Darus, Danijela Jelovac, Linda R. Duska, Gina R. Petroni, Lisa Barroilhet, Jubilee Brown, Nikole Varhegyi, Kathleen N. Moore, Angeles Alvarez Secord, William P. McGuire
Publikováno v:
Gynecologic Oncology. 157:585-592
Angiogenesis inhibition is a valuable strategy for ovarian cancer (EOC). Pazopanib (paz) is a potent small molecular inhibitor of VEGF-1, -2, -3, PDGFR, c-kit, and has activity as a single agent in ovarian cancer. We designed a trial to assess the be
Autor:
Nicole M. Kretzer, Fernanda B. Musa, Christopher J. Darus, Nancy Biery, Roshanthi Weerasinghe, Ann Vita, Shwetha Pindikuri, Amy S. Parrish, Grace Li, Charles W. Drescher
Publikováno v:
Gynecologic Oncology Reports. 44:S26
Autor:
Nicole M. Kretzer, Christopher J. Darus, Nancy Biery, Roshanthi Weerasinghe, Grace Li, Ann Vita, Shwetha Pindikuri, Amy S. Parrish, Charles W. Drescher, Fernanda B. Musa
Publikováno v:
Gynecologic Oncology Reports. 44:S13
Autor:
Jay W. Carlson, Robert S. Mannel, Vicky Makker, Carol Aghajanian, Erin K. Crane, David Bender, Christopher J. Darus, Ursula A. Matulonis, Michael W. Sill, David G. Mutch
Publikováno v:
Gynecologic Oncology. 152:548-553
Introduction Cabozantinib is a receptor tyrosine kinases inhibitor that targets MET (c-MET), VEGF receptor 2 (VEGFR2), RET, AXL, KIT, FLT-3, and TIE-2 and previously showed promising single agent activity in recurrent ovarian cancer. Methods This was
Autor:
Luciana Molinero, Christopher J. Darus, Xiaohua Wu, Johanna Mäenpää, Charles K. Anderson, Nicoletta Colombo, Aikou Okamoto, Giovanni Scambia, Y. García, Fan Wu, Michael A. Bookman, Yvonne G. Lin, Victor Khor, L. Willmott, Jalid Sehouli, Tashanna Myers, Michalis Liontos, Rustem Safin, Michael A. Gold, Cagatay Taskiran, Katina Robison, Austin Miller, Vidya Maiya, Sudarshan K. Sharma, Carol Aghajanian, Sandro Pignata, Jessica Thomes-Pepin, Kathleen N. Moore
Publikováno v:
J Clin Oncol
Journal of Clinical Oncology
Journal of Clinical Oncology
Purpose: to evaluate the addition of the humanized monoclonal antiprogrammed death ligand-1 (PD-L1) antibody, atezolizumab, to platinum-based chemotherapy and bevacizumab in newly diagnosed stage III or IV ovarian cancer (OC). Methods: this multicent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ea89f9ab83f69d1132450dbd7ec3832
http://hdl.handle.net/10281/327598
http://hdl.handle.net/10281/327598
Autor:
Ramey D. Littell, William P. Tew, Aimee C. Fleury, Anthony Evans, Christopher J. Darus, Robert S. Mannel, Wei Deng, Gini F. Fleming, Susan C. Modesitt, Mitchell I. Edelson, Amina Ahmed, David Bender, Albert S. DeNittis, Jay W. Carlson, Mark A. Morgan, Alexander B. Olawaiye
Publikováno v:
Gynecologic oncology, vol 150, iss 2
Introduction CC-002 is a prospective cooperative group study conducted by NRG Oncology to evaluate whether a pre-operative GA-GYN score derived from a predictive model utilizing components of an abbreviated geriatric assessment (GA) is associated wit
Autor:
Vicky Makker, Virginia L. Filiaci, Katherine M. Moxley, Carol Aghajanian, Christopher J. Darus, Gregory P. Sutton, Lee-may Chen, James E. Kendrick
Publikováno v:
Gynecologic oncology, vol 138, iss 1
Objective This two-stage phase II study assessed activity of single agent dalantercept in patients with recurrent/persistent endometrial carcinoma (EMC). Methods Eligible patients had persistent/recurrent EMC after 1–2 prior cytotoxic regimens, mea
Autor:
Robert L. Coleman, Lainie P. Martin, Jeanne M. Schilder, Bradley J. Monk, Gregory P. Sutton, Krishnansu S. Tewari, Jai Balkissoon, Joan L. Walker, Carol Aghajanian, Michael W. Sill, Christopher J. Darus
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(19)
Purpose The vascular disrupting agent fosbretabulin tromethamine selectively targets pre-existing tumor vasculature, which causes vascular shutdown and leads to cancer cell death and necrosis. Antiangiogenesis agents such as bevacizumab, a humanized